Clinical
Research:
Oscillococcinum has been shown to decrease symptoms of flu for a
significant number of patients.
A double-blind, placebo-controlled pilot study
of 100 patients showed that, when given at the onset of
influenza-like symptoms, Oscillococcinum worked better than the
placebo in reducing the symptoms of chills (85.7% vs. 57.1%),
stiffness (72.5% vs. 41.9%) and fever (79.1% vs. 40%). Also 80% of
patients given Oscillococcinum’ reported the treatment to be a
success vs. 38% in the placebo group.’
In a double-blind, clinical trial of 300
patients with influenza-like symptoms, 55% of the
patients taking Oscillococcinum’ reported no chills after four days,
compared with 27% of the placebo- controlled group. More patients in
the Oscillo’ group also reported no aches after four days-70% were
ache-free compared with 48% in the placebo group. Fever in the
Oscillococcinum’ group was significantly lower starting on the I
second day of the treatment, compared to the placebo group.’
In a double-blind, clinical trial of 478
patients published in The British Journal of Clinical
Pharmacology in 1989, researchers studied Oscillococcinum’s effect
on nine influenza-like symptoms-fever, headaches, stiffness, lumbar
and particular pain, shivers, cough, coryza and fatigue - versus a
placebo. The proportion of patients who recovered within 48 hours
of treatment was significantly superior among the Oscillo group than
the placebo group.
A recent double-blind, clinical trial of
372 patients performed by f researchers at a German
University and published in April 1998 yielded results similar to
those published in the British Journal of Clinical Pharmacology
(above). The complete disappearance of symptoms after 48 hours was
significantly superior among the Oscillo group than among the
placebo group. This clinical trial also showed that treatment of
influenza-like symptoms with Oscillococcinum’ has positive effect on
the decline of symptoms and on the duration of the disease.